TOMORROW’S CURES BEGIN TODAY
LEADING THE TRANSFORMATION OF CANCER CARE
DEAR FRIEND OF KARMANOS,
As president and CEO of the Barbara Ann Karmanos Cancer Institute, I continue to be struck by the remarkable qualities that elevate Karmanos and align our institution with the nation’s leading organizations also grappling with the realities of cancer.
From our recognition as a National Cancer Institute (NCI)-designated Comprehensive Cancer Center, to the combination of leading-edge research with a concurrent commitment to extraordinary patient care, Karmanos embodies attributes that make it distinctive. With the Wayne State University School of Medicine as an academic partner and McLaren Health Care ensuring professional standards and fiscal acumen, Karmanos continues excellent patient treatment, breakthrough research, and transformative cancer therapies with the single objective of curing cancer. As a national leader in cancer treatment and research, the future of Karmanos is exciting and dynamic.
In addition to these qualities, Karmanos is located within a city undergoing a remarkable resurgence. With extraordinary diversity and international access points, our Detroit metropolitan location offers advantages no other national institution can deliver. Through its 17 locations, we treat more cancer patients than any other health care facility in the state. But more work must be done.
Karmanos’ transformation to the highest level of research and patient care is critical in realizing the vision of a cancer-free world. This is a monumental task, but no task is impossible with caring, dedicated friends. The time is now to move to the next level of care that could save you, your loved ones’, friends’, or neighbors’ lives.
Together, we can win the battle of this disease and extend the lives of our community and all those who come to Karmanos searching for hope and a new chapter in life.
Sincerely,
Boris C. Pasche, M.D., Ph.D. President and Chief Executive Officer
Karmanos Cancer Institute
HISTORY
The Barbara Ann Karmanos Cancer Institute can trace its roots back many years ago in its commitment to pioneering cancer research and advancing treatments. In 1943, the seeds were sown to coalesce academic excellence, research, and patient care into one of the country’s most cutting-edge healthcare institutions by officially forming The Detroit Institute for Cancer Research. Soon after, it was renamed the Michigan Cancer Foundation.
In 1974, it centralized numerous cancer research, teaching, and treatment activities under a unique and progressive entity. Due to the dynamic relationship with Wayne State University, Detroit Medical Center, and Harper Hospital, the Michigan Cancer Center was designated a Comprehensive Cancer Center in 1978 by the National Cancer Institute (NCI), the federal government’s principal cancer research and training agency. In 1995, the Michigan Cancer Foundation was renamed the Barbara Ann Karmanos Cancer Institute in honor of the late wife of Detroit businessman and philanthropist Peter Karmanos, Jr.
For more than 46 years, the Karmanos Cancer Institute has become the exemplar of Comprehensive Cancer Centers, combining basic research, translational research, cancer prevention and control, and leadingedge cancer treatment. Karmanos is one of 57 in the country and the first of only two in the state of Michigan.
The Barbara Ann Karmanos Cancer Institute was the first in Michigan to be designated as an NCI-Designated Comprehensive Cancer Center by the National Cancer Institute in 1978. We have been an exemplary beacon for cancer care for more than 46 years, combining basic research, translational research, cancer prevention and control, and leading-edge cancer treatment. I am proud that Karmanos is one of 57 in the United States with this elite designation. The Barbara Ann Karmanos Cancer Institute exemplifies excellence and is a leader in transformative cancer care, research and education through courage, commitment, and compassion.
Peter Karmanos, Jr.
Karmanos Board of Directors
A LEGACY OF GENEROSITY
Throughout the decades, many generous individuals, foundations, and corporations have provided resources in the ongoing fight against cancer. Karmanos Cancer Institute is blessed with dedicated and loyal donors who continue to make a significant impact on research, facilities, and patient care. Philanthropy allows Karmanos the opportunity to “push the envelope” with unique and ambitious approaches to cancer care.
Some of these transformational gifts include the Walt Breast Center, Weisberg Cancer Treatment Center, Joseph Dresner Family Clinic for Hematologic Malignancies and Stem Cell Transplantation, Eisenberg Center for Transplantation Therapeutics, Gershenson Radiation Oncology Center, Wertz Clinical Cancer Center, and the J.P. McCarthy Cord Stem Cell Bank.
These gifts represent a few of the generous contributions and their impact on Karmanos. In addition, significant research funds have been made available through individual generosity. Charitable gifts at Karmanos play a distinct and unique role by allowing physicians, researchers, and staff to explore and discover new cures and treatments. All donations have an impact and are needed to move forward in new directions, creating novel approaches to benefit those who come to Karmanos.
The difference between maintaining the status quo and being a leader in cancer care comes down to generous individuals who partner with Karmanos to forge a world free of cancer. Please join us in this effort.
TODAY
Physicians, nurses, researchers, and staff are motivated to fight for our patients’ lives with professionalism and determination. What was once a single location in Detroit now provides state-of-the-art care in Southeast Michigan, up to Northern Michigan, west near the Red Cedar River in Lansing, and down to the Maumee River in Northern Ohio. Karmanos is proud to provide the latest and most progressive cancer treatments throughout the McLaren Health Care system.
Karmanos understands that beating cancer means bringing together the best professionals. Cancer is a complex disease that demands complex care. As an accredited NCI-Designated Comprehensive Cancer Center, our patients can access the most advanced cancer care in our communities.
We are among the nation’s best cancer centers, caring for approximately 14,000 patients annually. Karmanos conducts over 500 cancer-specific scientific investigation research projects and clinical trials at any given time. Karmanos offers one of the nation’s most extensive clinical trial programs, giving patients access to more than 250 promising new treatments often not found at other hospitals or health care organizations.
Through the dedication of 1,000 staff members, including nearly 300 faculty members, and supported by thousands of volunteers and donors, Karmanos leads in transformative cancer care, research, and education through courage, commitment, and compassion. Our long-term partnership with the Wayne State University School of Medicine enhances the collaboration of research and academics related to cancer care.
A National Cancer Institute Comprehensive Cancer Center
At the heart of Karmanos is its NCI Comprehensive Cancer Center Designation, which was earned in 1978. This level of recognition is hard-won and must be renewed every five years to ensure standards and quality are maintained. To be designated as a Comprehensive Cancer Center by the NCI, a hospital must:
• Demonstrate expertise in laboratory, clinical, behavioral, and population-based research.
• Initiate and conduct early-phase, innovative clinical trials and participate in the NCI’s cooperative groups by providing leadership and recruiting patients for trials.
• Conduct activities in outreach and education and provide information on advances in health care for health care professionals and the public.
NCI-Designated Comprehensive Cancer Centers are characterized by scientific excellence and the capability to integrate diverse research approaches, playing a vital role in reducing morbidity and mortality from cancer.
While many hospitals provide cancer treatment, few in the nation, such as Karmanos, have the elements of an NCI-Designated Comprehensive Cancer Center. This unique combination results in scientific discoveries that become tomorrow’s cancer treatments. The synergies of NCI Comprehensive Cancer Centers make superior cancer treatment possible.
The Three Pillars to Karmanos’ Success
As the largest cancer research and cancer care network in Michigan, our patient care, research, and clinical care benefit 20% of patients diagnosed with cancer (one in every three patients) across the state.
PATIENT
CARE BASIC RESEARCH TRANSLATIONAL RESEARCH
Having an NCI-Designated Comprehensive Cancer Center in Detroit to serve the diverse population of Southeast Michigan and northern Ohio has been of incalculable value over many years. With the development of the Karmanos Cancer Network, we have expanded our mission throughout a large part of our state. Being a provider of world-class, industry-leading research and state-ofthe-art compassionate cancer care is a vital role Karmanos fills in our community. It is an honor to play a role in supporting the advancement of the Karmanos Cancer Institute and fulfilling its mission. I encourage everyone to join us in this important work.
Timothy Monahan Chair of the Board Karmanos Cancer Institute
PATIENT CARE
Karmanos has more expertise in numerous types of cancer than any other cancer center in Michigan. Many of the latest cancer-fighting medications approved by the U.S. Food and Drug Administration (FDA) were first tested here and are available to our patients. For example, Karmanos is the largest provider of CAR T-Cell therapy in Michigan, a treatment first offered as a clinical trial at Karmanos and at only 17 other centers worldwide. At Karmanos, we are providing options to fight cancer that did not exist as far back as yesterday. Our persistent objective is to lead in the fight against cancer, not follow. In 2023, Karmanos saw over 271,000 outpatient visits, administered 33,400 chemotherapy treatments, performed 2,240 surgeries, completed 22,240 radiation treatments, and conducted over 75,000 diagnostic imaging procedures.
While every hospital does what it can, we provide treatments not available in community hospitals or other medical centers through a comprehensive approach that’s unmatched. Our patients can access treatments exclusive to Karmanos, as well as clinical trials, cancer prevention programs, and multidisciplinary teams of cancer specialists.
This comprehensive approach cannot be found at a community hospital or other medical centers. We specialize in the most complex cases, including advanced cancer, because we are at the forefront of cancer research. We develop and translate innovative science into clinical practices in an unparalleled way, providing access to all patients.
Our daily mission is to provide superior care to patients diagnosed with the most challenging cancers.
The depth of expertise is more comprehensive than that of physicians, radiation therapists and nurses. It spreads to the pharmacy team, imaging technicians, and many others, creating a synergistic approach to care.
Additionally, through various support groups, educational programs, and therapy services, Karmanos strives to ensure that patients and caregivers have the tools and resources to care for their bodies, mind, spirit, and basic needs.
Researchers collaborating with physicians and other patient care providers is a hallmark of Karmanos. Physical proximity matters, and having professionals interact and be close to one another builds the dynamic exchange of ideas that become tomorrow’s breakthroughs.
BASIC RESEARCH
Our patients benefit from many dedicated researchers investigating the causes and treatments for cancers at the molecular level. These scientists create breakthroughs that are the foundation of new pharmaceuticals, medical devices, imaging processes, advanced cancer treatments, and diagnostic methods.
In 2023 alone, 322 scientific publications were produced, including 64 peer-reviewed funded projects supported by grants from the National Institute of Health (NIH) and the U.S. Department of Defense. These investigations lead to new information and expanded knowledge for improving cancer care. Karmanos has over 70 scientific members who contribute to three basic science research programs – Molecular Imaging, Molecular Therapeutics, and Tumor Biology and Microenvironment – all engaging in research labs. Discoveries from these efforts are shared through peer-reviewed journals and disseminated throughout the scientific world.
Decades of Breakthrough Discoveries
1960s
1960s: Jerome Horowitz, Ph.D., a medicinal chemist specializing in the synthesis of nucleoside drugs for cancer, synthesized AZT as an anti-leukemia agent. AZT later became the first drug approved for the treatment of AIDS.
1970s 1990s
1970s: Herbert Soule, Ph.D., established the first “immortal” line of human breast cancer cells, MCF-7. The line became the standard for breast cancer research throughout the world.
1990s: Anthony Shields, M.D., Ph.D., developed FLT as a new positron emission tomography tracer to identify cancer cells.
Wei-Zen Wei, Ph.D., developed the HER2 DNA breast cancer vaccine.
Karmanos continues to grow the basic science research programs through aggressive targeted recruiting of new faculty and scientists. While expanding our reach into a broad array of investigation subjects, we are particularly focused on research designed to identify new therapeutic targets involving cancer-specific processes and theranostics, which provide a two-pronged strategy for simultaneously diagnosing and treating cancers.
Karmanos researchers focus on biological processes that go awry in cancer cells involving cancer metabolism as well as state-of-the-art metabolomics analysis. In addition, Karmanos is prioritizing studying the immune system in cancer progression and its potential in cancer therapy. Basic laboratory research focuses on cancers that are disproportionately reported in the underrepresented populations throughout Detroit.
2000s 2010s 2020s
2000s: A clinical prototype of an ultrasound tomography (UST) device was created at Karmanos.
2010s: CAR T-cell therapy received FDA approval; Karmanos was one of 18 sites worldwide that participated in developing this cuttingedge, immune-based technology.
2020s: Boris Pasche, M.D., Ph.D., FACP, president and CEO of Karmanos, coinvented the TheraBionic P1 device, which received FDA approval in 2023 for treating advanced hepatocellular carcinoma.
TRANSLATIONAL RESEARCH
While most medical centers use best practices in cancer care, Karmanos discovers new therapies that become best practices.
Translational research moves discoveries from basic sciences to patient care (bench to bedside). Ultimately, translational research speeds up the adoption of best practices in hospitals nationwide. While most medical centers use best practices in cancer care, Karmanos discovers new therapies that become best practices. We are constantly pushing the boundaries of innovation by introducing novel treatments and producing the cures of the future. This research results in FDA approval, becoming the standard of care other institutions adopt.
With more than 500 current research projects being conducted, Karmanos significantly impacts the body of academic knowledge but, more importantly, saves lives. Karmanos is nationally recognized for the quality of translational research. Due to our population density and diverse community, the research conducted benefiting our patients is unique in the country.
The multidisciplinary teams focusing on specific types of cancer ensure synergistic relationships with physicians, nurses, researchers, pharmacists, and technicians across disease lines to produce the very best ideas for research projects. Bringing research into the cancer fight is ingrained in our history and part of our character. Research is not something we will work on when time allows, nor is it a diversion from patient care. Research is the engine that makes Karmanos an essential part of the national health care community.
CLINICAL TRIALS
A critical element of translational research is clinical trials. These trials consist of new and experimental drugs for cancer patients and are often their best and only chance for a cure. Every patient is eligible to participate in clinical trials of new drug therapies, regardless of their economic standing. Everyone deserves the opportunity to fight for their life with experimental treatments.
Expanding translational research to other Karmanos locations is imperative for the future. Additional locations within the Karmanos Cancer Network, such as our locations in Flint and Lansing, mean more patients can be helped and given the opportunity for a cure. When all options are exhausted for a patient, clinical trials offer hope. What we learn from these trials and patients can be tomorrow’s answers to treating cancer.
Research is not something we will work on when time allows, nor is it a diversion from patient care. Research is the engine that makes Karmanos an essential part of the national health care community.
“With the exceptional care of the doctors and staff at Karmanos, as well as my supportive caregivers, we’ve accomplished great things. It really inspires hope.”
– John Raithel
FUTURE
Throughout its history, the Karmanos Cancer Institute has maintained an attitude of innovation and determination in fighting cancer. Homegrown grit drives our commitment to finding cures for cancer, pioneering more effective drug therapies, expanding clinical trials to accelerate treatment options for patients, and pushing the boundaries of scientific research to discover breakthroughs. Over the decades, nurses, physicians, caretakers, and researchers at the Karmanos Cancer Institute have rolled up their sleeves daily to meet the needs of the people of Detroit and throughout Michigan.
As the region’s diverse citizens unite to fight cancer, Karmanos will move forward with the same selfless attitude that characterizes our future. Each person deserves world-class cancer treatment in their community. Our history is a treasure, and the future is even brighter.
PATIENT CARE
Karmanos is uniquely positioned to elevate patient care in lung, breast, colon, multiple myeloma, pancreas, and liver cancers. These cancers are among the most devastating and challenging illnesses, and Karmanos is moving beyond current treatment options to implement the most innovative and effective options possible.
Also among the most challenging cancers are amyloidosis, leukemia, lymphomas and multiple myeloma. We provide a world-class Bone Marrow and Stem Cell Transplant (BMT) Program at Karmanos, giving patients more hope. Data released by the Center for International Blood and Marrow Transplant Registry shows that Karmanos’ BMT program is one of only a select group nationwide reporting some of the best survival outcomes for related and unrelated stem cell transplantation.
Our physicians, nurses, and technicians create dynamic and complementary teams providing excellent care. This can only happen when professionals have the best equipment, facilities, and resources focused on a singular outcome of excellence for patients.
PHASE I CLINICAL TRIALS EXPANSION
Karmanos is committed to expanding its clinical trials program, including staff and resources. The objective is to extend the Phase 1 Clinical Trials Program to other locations in the Karmanos Cancer Network, beginning with Flint and Lansing, opening opportunities for participation in an expanded geographic area. Funds are required to procure more staff, instrumentation, and laboratory space. Upgraded facilities are needed for specialized blood draw equipment and tumor biopsy preservation areas. Karmanos is among the few health care organizations that can manage multiple clinical trial programs effectively. Our responsibility and vision are to offer
clinical trials in as many areas as possible. We are the only Comprehensive Cancer Center in Michigan that can provide clinical trials at additional locations outside of our headquarters. By expanding our reach, Karmanos will elevate our role as a national leader in clinical trials.
THERANOSTICS
Theranostics refers to pairing diagnostic biomarkers with therapeutic agents that share a specific target in diseased cells or tissues. Nuclear medicine, particularly regarding applications in oncology, is currently one of the most significant components of the theranostic concept in clinical and research scenarios. Theranostics in nuclear medicine refers to using radioactive compounds to image biological phenomena by means of expressing specific disease targets, such as cell surface receptors or membrane transporters. Specifically designed agents are then used to deliver ionizing radiation to the tissues that express these targets. Karmanos seeks to lead the nation in research and treatment using this technique.
The objective is to establish a world-class program in Detroit, including the Lansing and Flint locations, to provide these therapies to as many cancer patients as possible.
FUTURE RESEARCH TOWER IN PARTNERSHIP WITH WAYNE STATE UNIVERSITY
Karmanos’ basic research program needs to be expanded to meet the needs of our patients. A bold step is a plan to construct a research tower focused on cancer research, allowing Karmanos and Wayne State University to develop breakthrough technologies and treatments with the latest cancer-specific science. Complete with modern facilities and the most advanced equipment, this proposed KarmanosWayne State partnership will be a national leader in the fight against cancer.
Karmanos is not seeking to be among one of the crowds of hospitals in Michigan, but to set the pace for others to aspire.
NEED FOR SUPPORT
Karmanos’ task is to lead the way in discovering cures for cancer and remain the pacesetter for others to aspire. As a comprehensive cancer center, Karmanos embraces the responsibility of continuing to chart a course that leads to innovation and breakthroughs. Karmanos’ history has been one of risk and relentless pursuit of the impossible. That is our charge for the future: Karmanos is never satisfied with the status quo because our patients deserve the very best, not only in treatment but also in research and application of knowledge to novel drug therapies that are not available at other medical centers.
“I chose Karmanos because they solely specialize in cancer, and if we are fortunate enough to have it in Michigan, where else would I go?”
- Josephine Roach
It is time to elevate Karmanos Cancer Institute’s reputation to the heights it deserves. The ingredients are here, and the opportunity is now to create the future of cancer care. Karmanos is a place of healing for all the people in our community, from those who have the means to choose any hospital in the nation to those struggling with financial instability. No matter their position in life, everyone deserves the very best.
Becoming a destination for cancer treatment takes generous partners. Philanthropic support is critical to making Karmanos a shining star in the country. Contributions provide the funds to conduct research that pushes the boundaries of discovery. Intellectual curiosity is merely a wishful thought until it is supported by benefactors. What Karmanos does today will determine the level of excellence in cancer care tomorrow.
Through philanthropic support, Karmanos can escalate its stellar reputation as a place of compassion, medical excellence, and scientific breakthroughs. Dedication allows Karmanos to take risks on new research, strive for industryleading treatments, and provide care for all community members. One day, you, a loved one, or a neighbor in the city may need the very best in cancer care.
Priorities for Funding
Karmanos Cancer Institute and Wayne State University celebrate a decades long partnership that has resulted in numerous novel breakthroughs in cancer research that have benefited our community. Our deep, dynamic affiliation was forged by dedicated scientists seeking to cure cancer. It is with that same unstoppable determination that together we, Karmanos Cancer Institute and Wayne State University, will write the next chapters of scientific innovation and discovery that will positively impact our health.
Kimberly A. Espy, Ph.D. President Wayne State University
ENDOWED CHAIRS
Endowed chairs offer permanence in research by funding an eminent physician-researcher in a particular discipline or disease line. These funds enable research projects to move forward over long periods, guaranteeing a significant impact in the search for cures. These funds also support the mentorship of future clinicians and researchers in discovering answers and advancing cancer care.
RESEARCH FACILITY EXPANSION
Exceptional researchers need state-of-the-art facilities and instrumentation to accommodate additional staff and laboratories. Even the brightest minds are hindered by space and equipment limitations. When researchers have excellent facilities to conduct research, discoveries occur. The best minds need the best facilities to create and discover. State-ofthe-art laboratories aid greatly in recruiting top researchers from around the country.
PRESIDENT’S CANCER RESEARCH FUND
These funds, directed by the President and CEO of the Karmanos Cancer Institute, provide the flexibility to move quickly on industryleading research opportunities. These dollars are the seed money for undertaking novel and unconventional research projects, exploring innovative ideas that lead to discoveries, and increasing the possibility of garnering significant support from the NIH or other granting agencies.
RESEARCH PROGRAMS
Research programs are critical in advancing dynamic cancer breakthroughs that improve outcomes and save lives. However, such programs require significant financial support to be successful. Both endowment and restricted funding are needed to supplement research studies, specifically in diseases like breast, pancreatic, prostate, and lung cancer.
PATIENT CARE
Karmanos Cancer Institute focuses on helping patients recover and lead their best lives through compassionate care. At the heart of Karmanos is commitment and dedication to those we treat. Providing services and programs that support cancer patients and their families is critical to our mission.
PHYSICIAN-DIRECTED RESEARCH
Many of Karmanos physicians are also researchers. Funding their research in a specific cancer is critical to achieving breakthroughs that lead to cures. These research efforts present a unique opportunity for a donor and physician to collaborate and focus on a specific cancer. When a donor desires to find answers to the causes and cures of a particular cancer, physician-directed research presents an exciting opportunity.
ANNUAL FUND
Ongoing contributions to the Annual Fund are critical in providing seed money and flexibility in generating new ideas in the battle against cancer. These donations support research and operational needs and are a consistent stream of funding, allowing immediate use of the gifts to the hospital’s most pressing needs.
AN EXCITING FUTURE BEGINS WITH FINANCIAL STABILITY
The Barbara Ann Karmanos Cancer Institute and the Barbara Ann Karmanos Cancer Center (collectively, Karmanos) are committed to fiscal sustainability and stewardship. Donations and community support are vital to the essential care our patients need, including the life-changing clinical research underway to cure cancer. We support our dedicated colleagues who consistently deliver outstanding patient care experiences in a highquality, cost-effective manner.
As a subsidiary of McLaren Health Care, Karmanos reported a positive operating margin and significant financial reserves, creating a strong financial foundation for the future. Karmanos is committed to investment and compassionate care crucial to the health and well-being of the community.
“I am thankful to the doctors, nurses, and care teams at Karmanos. I recommend that anyone who receives a cancer diagnosis, ‘please go to Karmanos!’”
– Tiffany Bentley
Your Gift Will Save Lives
Karmanos Cancer Institute is a valuable asset to McLaren Health Care in that it meets a critical need for countless patients and their loved ones throughout Michigan and northern Ohio, providing them with a tremendous advantage.
With the clinical achievements and expanded patient access the organization has developed in our time together, we are proud to be in the position to offer the advantages of Karmanos to our patients and are encouraged for the future.
Philip A. Incarnati McLaren Health Care President and CEO
PROVIDING THE BEST CANCER CARE AVAILABLE
When you or a loved one receives the diagnosis of cancer, everything changes. As the second leading cause of death in the United States, cancer remains a devastating disease for those afflicted. Being treated at the best institution is critical to cure and survival. Investing in the Karmanos Cancer Institute means you, family members, neighbors and loved ones have access to the very best cancer care.
GUARANTEEING THE BEST CANCER CARE CLOSE TO HOME
Access to the best care in your own community is exceptionally important to every patient. Knowing that a world-class cancer center is located a brief car ride away is a tremendous comfort to those in Metro Detroit and the surrounding community. Traveling out of the state or across the country is not an option for most individuals seeking treatment. Exceptional care in their hometown is essential. In some cases, recovering from cancer surgery is safer and less complicated when closer to home. Many forms of cancer treatment include reoccurring radiation or chemotherapy visits, and thus, traveling is not possible.
CREATING AND MAINTAINING HEALTHY COMMUNITIES
Detroit is blessed with several prominent hospitals, but Karmanos stands out in cancer care. The health of a city is measured by the quality of organizations that provide care. The results of exemplary cancer care lead to healthier communities. Proactive screenings, early detection, novel therapies, leading-edge radiation therapy, and specialized surgical procedures create a city where people have the resources to live better, healthier lives.
ATTRACTING AND KEEPING RESIDENTS IN MICHIGAN
A superior cancer center is an endorsement of the quality of life in a region. Having excellent healthcare facilities available makes metro Detroit more attractive for people to relocate to and live. Michigan was home to 29 Fortune 500 companies in 2023. Attracting executive talent and skilled workers is critical to enhancing Michigan as a forward-looking state in commerce. Exceptional healthcare, which attracts and fosters biotech and medtech development, is a prime factor in moving a state forward. It is also imperative to retain Michiganders living, growing, and raising families in the state.
PARTICIPATING IN THE RE-BIRTH OF DETROIT
In 2013, Detroit declared the largest municipal bankruptcy in the nation. At the time, many critics scoffed that it was the end of the city. Detroit proved the critics wrong, and in only ten short years, the city is experiencing a revival that is a model for other urban areas. Enhancing the visibility and impact of a nationally recognized NCI-designated Comprehensive Cancer Center is a unique opportunity to participate in the rebirth of our great city. Expanding a world-class cancer center is something that will make a historic difference. Your support will not only help save lives but also uplift the city and state.
Board of Directors
Geaneen Arends
Dawn Aronoff
Greg Avsharian
David Drews
Michael Duhaime
David E. Duprey
Kimberly Espy, Ph.D.
Shari Ferber-Kaufman
Mark Flynn
Myron Frasier
Adnan Hammad, Ph.D.
Sylvester Hester
Scott Hunter
Thomas Kalas
Peter Karmanos, Jr.
Kelley LaFontaine
Mary Matuja
Timothy Monahan
Debra Partrich
Daniel Ret
Wael Sakr, M.D.
Deborah Savoie
We are so thankful to so many who have supported Karmanos Cancer Institute over the years, which has enabled us to provide state-of-the-art clinics for our oncology patients and their families. These amazing jewels include the Alexander Walt Breast Center, Joseph E. Dresner Family Clinic for Hematologic Malignancies and Stem Cell Transplantation, Eisenberg Center for Translational Therapeutics, Gershenson Radiation Oncology Center, Wertz Clinical Cancer Center, and the Lawrence & Idell Weisberg Cancer Center, providing basic research, translational research, cancer prevention and control, and leading-edge cancer treatment.
Debra Partrich Karmanos Board of Directors
Karmanos Cancer Institute focuses on maintaining healthy communities in Southeast Michigan and the state. As an NCI-Designated Comprehensive Cancer Center, Karmanos is steadfast in addressing health disparities through education and advocacy while communicating with community groups to make a significant difference in the lives of our cancer survivors.
Geaneen Arends Karmanos Board of Directors
Karmanos provides patients access to care close to home. As a national leader, Karmanos physicians and scientists are engaged daily in developing breakthrough technologies and treatments with the latest cancer-specific sciences. Patients have access to treatments exclusive to Karmanos, as well as clinical trials, cancer prevention programs and multidisciplinary teams of cancer specialists — a comprehensive approach you cannot find at a community hospital. A cancer diagnosis is not the end of the story but the beginning of a new chapter. Karmanos provides patients and families their best chance while supporting them during their successful cancer journey.
Dick Purtan Former Karmanos Board of Directors Member
Karmanos Locations
Karmanos